VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

VALBIOTIS

VALBIOTIS opens up its capital to a new shareholder, AMIRAL GESTION.

Read more

TOTUM-63

First Patient First Visit in the international Phase II/III REVERSE-IT clinical study on TOTUM-63 to reduce Type 2 Diabetes risk factors.

Learn more

TOTUM-63

VALBIOTIS: authorization to launch the international Phase II/III REVERSE-IT clinical study on TOTUM-63, to reduce Type 2 Diabetes risk factors.

Learn more

Pipeline

VALBIOTIS accelerates the clinical development of its pipeline in new indications: reducing cardiovascular risk and hepatic steatosis.

Learn more

VALBIOTIS

VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE for the development and commercialization of TOTUM-63

Learn more
S c r o l l

Products

.01

TOTUM-63

Prediabetes, risk condition for Type 2 Diabetes
> Clinical Phase II positive
> Clinical Phase II/III pending

Learn more

.02

TOTUM-070

Mild to moderate hypercholesterolemia, risk factor for cardiovascular diseases
> Clinical Phase II pending

Learn more

.03

TOTUM-448

Non-alcoholic hepatic steatosis, risk condition for NASH
> Clinical Phase II pending

Learn more

.04

TOTUM-854

Elevated blood pressure, a risk factor for cardiovascular diseases
> Clinical Phase II pending

Learn more

Key figures

Patent families filed

4
All exploitation rights obtained

Employees

> 35
75% in R&D

Listed on the Stock Exchange

2017
Euronext Growth

Our last posts

12.06.2020

80th scientific sessions of the American Diabetes Association

En savoir plus
11.02.2020

Investor meetings – Portzamparc

En savoir plus
28.01.2020

Biomed Event

En savoir plus
16.10.2019

French Society of Financial Analysts (SFAF)

En savoir plus
Voir tous

VALBIOTIS© listed on the Stock Exchange

Learn more

Follow us!

See more